69964-40-5

Usage

Derivative of 2H-chromene

benzopyran compound
2,2-dimethyl-2H-chromene-6-carbaldehyde is derived from the parent compound 2H-chromene, which is a type of benzopyran, a fused bicyclic compound consisting of a benzene ring and a pyran ring.

-6-carbaldehyde suffix

The suffix "-6-carbaldehyde" signifies the presence of an aldehyde functional group (a carbonyl group bonded to a hydrogen atom and an alkyl or aryl group) at the sixth carbon atom of the chromene ring in the compound.

Usage in organic synthesis and medicinal chemistry

2,2-dimethyl-2H-chromene-6-carbaldehyde is commonly used as a precursor in the preparation of various pharmaceuticals and bioactive molecules, making it a valuable building block in the synthesis of complex organic compounds.

Specific properties and applications

The specific properties and applications of 2,2-dimethyl-2H-chromene-6-carbaldehyde depend on its individual characteristics, such as reactivity and stability, as well as how it is used in combination with other chemicals in various chemical reactions and processes.

Upstream product

• 61370-75-0 3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-carboxaldehyde 
• 54730-31-3 4-((2-methylbut-3-yn-2-yl)oxy)benzaldehyde 
• 1111-97-3 3-chloro-3-methylbut-1-yne 
• 123-08-0 4-hydroxy-benzaldehyde 
• 107-86-8 3,3-dimethyl acrylaldehyde 
• 54730-30-2 4-hydroxy-3-C-prenylbenzaldehyde 
• 106-44-5 p-cresol 
• 78-79-5 isoprene 
• 33143-29-2 6-cyano-2,2-dimethylchromene 
• 87-69-4 tartaric acid 
• 74021-58-2 4-methoxymethoxy-3-(3-methyl-but-2-enyl)-benzaldehyde 
• 870-63-3 prenyl bromide 
• 23446-57-3 2,2,6-trimethyl-3,4-dihydro-2H-chromene 
• 82305-04-2 6-bromo-2,2-dimethyl-2H-chromene 

Downstream Products

• 71822-00-9 <1-hydroxyethyl>-2,2-dimethylchromene 
• 130236-69-0 4',6'-bisethoxymethoxy-2'-hydroxy-6'',6''-dimethyl-3',5'-di-C-prenylpyrano<2'',3'',4,3>chalcone 
• 122850-53-7 Z-Lonchocarpene 
• 103805-58-9 E-Lonchocarpene 
• 34818-56-9 anofinic acid 
• 158257-64-8 (4-Chloro-phenyl)-(2,2-dimethyl-2H-chromen-6-yl)-methanol 
• 72934-63-5 (E)-3-(2,2-dimethyl-2H-chromen-6-yl)-1-(2-hydroxy-4-methoxymethyloxyphenyl)-2-propen-1-one 
• 217442-54-1 (E)-3-(2,2-dimethyl-2H-chromen-6-yl)-1-(2-hydroxy-4,6-dimethoxymethyloxyphenyl)-2-propen-1-one 
• 217442-56-3 (E)-3-(2,2-dimethyl-2H-chromen-6-yl)-1-[2-hydroxy-5-(3,3-dimethylallyl)-4-methoxymethyloxyphenyl]-2-propen-1-one 
• 217442-57-4 (E)-3-(2,2-dimethyl-2H-chromen-6-yl)-1-[2-hydroxy-3,5-bis(3,3-dimethylallyl)-4-methoxymethyloxyphenyl]-2-propen-1-one 
• 158257-65-9 (4-Chloro-phenyl)-(2,2-dimethyl-2H-chromen-6-yl)-methanone 
• 1342891-34-2 N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]aniline 
• 1342890-46-3 (2,2-dimethyl-2H-chromen-6-ylmethyl)-(2-fluorophenyl)amine 
• 927823-05-0 2,5-dichloro-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide 

Relevant academic research and scientific papers

Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation

A series of flavonoid-triazolyl hybrids were synthesized and evaluated as novel inhibitors of hepatitis C virus (HCV). The results of anti-HCV activity assays showed that most of the synthesized derivatives at a concentration of 100 μg/mL inhibited the ge

Synthesis of new 2,2-dimethyl-2H-chromen derivatives as potential anticancer agents

The synthesis of some new heterocyclic derivatives comprising imidazothaidiazole, diaryl ketone and chromen as starting compound has been reported. The new series of chromen analogues have been synthesized. The reaction has been monitored by Thin Layer Chromatography (TLC) using suitable mobile phase. The Rf values have been compared and the melting points of derivatives determined. Further, these derivatives have been characterized and confirmed by IR,1H NMR and mass spectral (MS) studies. All the selected compounds submitted to National Cancer Institute (NCI) for in vitro anticancer assay have been evaluated for their anticancer activity.

Butenolide derivative as well as preparation method and application thereof

The invention discloses a butenolide compound as well as a preparation method and an application thereof. The butenolide derivative has the inhibitory activity of protein tyrosine phosphatase 1B (PTP1B), improves insulin resistance of HepG2 cells, generates a remarkable hypoglycemic effect and can be used for preparing a medicine for treating diabetes mellitus.

Flavanone derivative as well as preparation method and application thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a flavanone derivative, a pharmaceutical composition of the flavanone derivative serving as an active ingredient, a preparation methods of the flavanone deriv

Synthesis method and use of natural product Angusticornin A

The invention discloses a synthesis method and use of a natural product that is Angusticornin A. The structure formula (I) of the natural product is shown in the description. The obtained natural product Angusticornin A has good inhibitory activity agains

Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents

The development of novel neuroprotection agents is of great significance for the treatment of ischemic stroke. In this study, a series of compounds comprising 2,2-dimethylbenzopyran groups and cinnamic acid groups have been synthesized. Preferential combination principles and bioisostere that improved the neuroprotective effect of the compounds were identified for this series via biological activity assay in vitro. Meanwhile, a functional reversal group of the acrylamide amide resulted in the most active compounds. Among them, BN-07 significantly improved the morphology of neurons and obviously increased cell survival rate of primary neurons induced by oxygen glucose deprivation (OGD), superior to clinically used anti-ischemic stroke drug edaravone (Eda). Overall, our findings may provide an alternative strategy for the design of novel anti-ischemic stroke agents with more potency than Eda.

2,2-dimethylbenzopyran derivative and preparation method and use thereof

The invention belongs to the technical field of medicines, and discloses a 2,2-dimethylbenzopyran derivative and a preparation method and use of the 2,2-dimethylbenzopyran derivative. The derivative and pharmaceutically acceptable salt of the derivative have the structural formulae shown in the description, wherein Ar, Ar, X, Y and R1 are as described in the claims and the description. The preparation methods of the derivative and the pharmaceutically acceptable salt of the derivative comprise the following steps: the formula (I) is obtained by mainly taking acetaminophen as a raw material, and subjected to the reactions of Williamson ether formation, cyclization, hydrolysis, amide formation and the like; the formula II is obtained by mainly taking p-hydroxybenzaldehyde as a raw material, and subjected to the reactions of the Williamson ether formation, cyclization, Knoevenagel condensation, amide formation and the like. The derivative and the pharmaceutically acceptable salt ofthe derivative disclosed by the invention can be used for preparing neuroprotective agents and have better neuroprotective effects on ischemic stroke.

Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway

Many forms of solid tumor have a characteristic feature known as hypoxia, which describes a low or non-existent presence of oxygen in the cellular microenvironment. This decrease in oxygen causes activation of the hypoxia inducible factor (HIF) pathway, w

Efficient, collective synthesis and nitric oxide inhibitory activity of rubrolides E, F, R, S and their derivatives

An efficient first synthesis of biologically significant natural butenolides, rubrolides F (1f), R (1r), S (1s) & its 7″,8″-didehydro derivative (1sa), and 3″-bromo rubrolide (1fa) along with the synthesis of rubrolide E (1e) and its di-O-methyl derivative (1ea) is accomplished in a collective fashion from commercially available and inexpensive precursors in overall yields of 14–48.5%. Key features are Wittig-Horner reaction, SeO2-induced tandem allylic hydroxylation/intramolecular cyclization and Knoevenagel condensation. Next, in their inhibitory activity towards nitric oxide (NO) production in lipopolysaccharide-induced RAW 264.7 macrophages as an indicator of anti-inflammatory activity, all compounds displayed good inhibitory activity in a concentration-dependent manner. None of the compound exhibited notable cytotoxicity at the highest concentration (10?μM) and IC50values are found in the range from 8.53 to 17.85?μM.

Synthetic method for rubrolide compounds E, F, R, S and their derivatives

Rubrolide F (compound 1f), R (compound 1r), and S (compound 1s), which are biological important natural butenolides, 7andPrime;,8andPrime;-didihydro derivatives (compound 1sa) thereof, 3andPrime; -bromorubrolide (compound 1fa), rubrolide E (compound 1e) and di-O-methyl derivatives thereof (compound 1ea) can be industrially obtained and are effectively synthesized with the overall yield of 14-48.5% from low-priced precursors. The rubrolide compounds can be synthesized through a Knoevenagel condensation reaction after a Wittig-Horner reaction and SeO_2-induced tandem allylic hydroxylation/intramolecular cyclization for preparing butenolide rings and a rubrolide cores structure.COPYRIGHT KIPO 2017